Compare ODC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | TNGX |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 1.4B |
| IPO Year | N/A | N/A |
| Metric | ODC | TNGX |
|---|---|---|
| Price | $53.27 | $10.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 55.5K | ★ 3.2M |
| Earning Date | 12-08-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 3.70 | N/A |
| Revenue | ★ $485,572,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $20.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | 10.97 | ★ 53.29 |
| 52 Week Low | $33.55 | $1.03 |
| 52 Week High | $69.76 | $11.20 |
| Indicator | ODC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 74.92 |
| Support Level | $53.11 | $9.90 |
| Resistance Level | $56.20 | $11.20 |
| Average True Range (ATR) | 1.41 | 0.72 |
| MACD | 0.01 | 0.30 |
| Stochastic Oscillator | 10.92 | 91.11 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.